Scleroderma (Systemic Sclerosis) Supportive Care Protocol

Scleroderma (systemic sclerosis) is a rare autoimmune disease characterized by hardening and thickening of the skin and connective tissues. It can also affect internal organs including the lungs, heart, kidneys, and gastrointestinal tract. There are two main types: limited (affecting mainly skin of hands, face, and feet) and diffuse (more widespread skin involvement and higher risk of organ complications). Key features include Raynaud's phenomenon (fingers turning white then blue in cold), skin tightening, and various organ manifestations.

CRITICAL: Scleroderma requires comprehensive multidisciplinary care including rheumatology, pulmonology, cardiology, and gastroenterology depending on organ involvement. There is no cure, but treatments exist for specific manifestations: calcium channel blockers for Raynaud's, immunosuppressants for lung fibrosis (mycophenolate, nintedanib), ACE inhibitors for renal crisis, proton pump inhibitors for reflux, and prokinetics for GI dysmotility. Early detection and treatment of organ involvement is crucial. These supplements may provide supportive benefit but do not replace disease-specific medications. Always work with your scleroderma specialist.

* Vitamin D deficiency is very common in scleroderma and has been associated with more severe disease. Vitamin D has immunomodulatory effects and maintaining adequate levels supports bone health (important given reduced activity and possible steroid use).

* Omega-3 Fatty Acids have anti-inflammatory effects and may help with vascular manifestations. Some research suggests they could help with Raynaud's and potentially slow fibrosis progression.

* N-Acetyl Cysteine (NAC) is an antioxidant that may help protect against the oxidative stress seen in scleroderma. It's also a mucolytic, which may help if there's pulmonary involvement.

* Probiotics can help manage the gastrointestinal symptoms common in scleroderma, including bloating and small intestinal bacterial overgrowth (SIBO).

* Coenzyme Q10 supports mitochondrial function and may help with the profound fatigue common in scleroderma.

* Ginkgo Biloba may improve peripheral circulation and provide some benefit for Raynaud's phenomenon.

* Vitamin E is an antioxidant that may help protect skin and blood vessels.

* L-Arginine is a nitric oxide precursor that may help with vascular symptoms.

Expected timeline: Supplements provide ongoing support. Raynaud's management is lifelong. Disease course varies - some stabilize, others progress. Regular monitoring for organ involvement is essential.

Clinical Perspective

Systemic sclerosis (SSc): autoimmune connective tissue disease characterized by fibrosis, vasculopathy, and immune activation. Subtypes: limited cutaneous (lcSSc, anti-centromere antibodies, better prognosis but PAH risk) vs diffuse cutaneous (dcSSc, anti-Scl-70/topoisomerase antibodies, rapid skin progression, higher ILD/renal crisis risk). Raynaud's phenomenon: universal; often first symptom. Organ involvement: ILD (leading cause of death), PAH, renal crisis (ACEi-responsive emergency), GI dysmotility (esophagus through colon), cardiac (myocardial fibrosis, arrhythmias).

CRITICAL: No cure; treat manifestations. Raynaud's: CCBs (nifedipine, amlodipine), PDE5 inhibitors, iloprost. Skin fibrosis: limited options (mycophenolate, methotrexate early). ILD: mycophenolate, nintedanib, tocilizumab if progressive. PAH: ERA, PDE5i, prostacyclins (specialist management). Renal crisis: ACE inhibitors (captopril); avoid corticosteroids (can trigger). GI: PPIs (reflux), prokinetics (metoclopramide, erythromycin), treat SIBO. Annual screening: PFTs, echo, HRCT. Supplements are ADJUNCTIVE.

* Vitamin D (B-grade): Deficiency prevalent (60-80%). Clinical study: lower levels associated with disease severity (PMID: 26473620). Review: immunomodulatory role (PMID: 28957097). 2000-4000 IU daily; target 40-60 ng/mL.

* Omega-3 Fatty Acids (C-grade): Anti-inflammatory; vascular effects. Pilot study: potential vascular benefits (PMID: 20816054). 2-4g EPA+DHA daily.

* NAC (C-grade): Antioxidant; glutathione precursor. Review: potential for fibrotic conditions (PMID: 24091108). 600-1200mg BID.

* Probiotics (C-grade): GI support; SIBO treatment. Pilot study: GI symptom improvement (PMID: 28411170). 20-50 billion CFU daily.

* CoQ10 (C-grade): Mitochondrial support. Systematic review: fatigue/cardiac benefits (PMID: 25282031). 100-200mg daily.

* Ginkgo Biloba (C-grade): Circulation support. Clinical trial: Raynaud's improvement (PMID: 12084136). 120-240mg daily. Monitor with anticoagulants.

* Vitamin E (C-grade): Antioxidant. Review: autoimmune support (PMID: 17030906). 400 IU daily.

* L-Arginine (C-grade): Nitric oxide precursor. Review: vascular function (PMID: 14523640). 3-6g daily divided.

Biomarker targets: Skin score (mRSS), PFTs (FVC, DLCO), 6-minute walk test, NT-proBNP, autoantibodies, capillaroscopy.

Protocol notes: Multidisciplinary care essential: rheumatology, pulmonology, cardiology, GI, dermatology. Annual screening: PFTs, echocardiogram, HRCT (baseline and if symptomatic). PAH screening: annual echo, consider RHC if elevated sPAP. Raynaud's management: keep warm (core and extremities), smoking cessation, avoid vasoconstrictors. Digital ulcers: CCBs, PDE5 inhibitors, IV iloprost, bosentan prevention. Skin care: moisturizers, physical/occupational therapy for hand function. GI: elevate head of bed, small frequent meals, address SIBO with rotating antibiotics (rifaximin, neomycin). Nutrition: may need calorie supplementation if malabsorption. Calcinosis: limited treatment options. Exercise: important for function, fatigue management. Pregnancy: high risk - specialized care, avoid certain medications. Screen for overlap syndromes. Support groups helpful. Clinical trials available.

View All Protocols